INDUSTRY INSIGHTS

Navigating Schizophrenia Part 2: A Path to Stability Using Long-Acting Injectable Therapy – Expert Insights

Posted September 13, 2025

Part two of this four part video series from J&J highlights long-acting injectable (LAI) antipsychotics as a treatment option for schizophrenia. Unlike daily oral medications, LAIs are given every few weeks or months, which may help with consistent treatment, reduce relapses, and support stable symptom management. The event features research findings, perspectives from mental health professionals, and experiences from patients to discuss the potential role of LAIs in improving care for people living with schizophrenia.

To learn more, watch the video here.

Contributor: Johnson & Johnson – Dr. Christoph Correll, Dr. Leslie Citrome, Dr. Diana Perkins

Together, we can empower the lives of others. Contact Us
Summit Clinical Institute Logo

The Summit Clinical Institute is a dedicated internal Knowledge Lab committed to collaboration and data-driven research.

Contact

About

Inquiries